Skip to content
Prof. Dr. Mustafa Özdoğan · Medical Oncologist

Cancers with More Genetic Abnormalities May Respond Better to Immunotherapy

Cancers with More Genetic Abnormalities May Respond Better to Immunotherapy

Tumors with very many genetic mutations may trigger a strong immune response because they produce enough proteins (antigens) for the immune system to recognize as foreign. Melanoma, bladder and lung cancer are among the most mutated cancers.

Numerous tumor mutations arise from a genetic abnormality called mismatch repair deficiency, suppressing the cell’s ability to repair DNA damage. Scientists think tumors with these abnormalities may be more sensitive to immune checkpoint blockade .

Mismatch Repair Deficiency (MRD) is this DNA repair disorder, occurring in colorectal cancers at approximately 15%. It is less common in stomach, small bowel, endometrial, prostate and ovarian cancers. Lynch syndrome is an example where the abnormality may be inherited. More often, however, MRD develops randomly during life.

Research obtained evidence that tumors with MRD-type DNA repair defects are sensitive to cancer immunotherapy. The FDA subsequently approved Pembrolizumab for treating colorectal cancer patients with MRD.

Researchers also found Pembrolizumab more effective against MRD-associated endometrial, ampullary, duodenal and stomach cancers. Of 7 patients, 5 responded, with average progression-free time of 5.4 months.

Although small, this research opened a possible new treatment option for advanced cancers with MRD. More specifically, it shows that assessing tumor genetics may help identify immunotherapy beneficiaries with less regard to organ of origin. Already, cancers with DNA repair defects are thought potentially more sensitive to PD-1 blockade.

Sources

Le DT, Uram JN, Wang H, et al.
PD-1 blockade in tumors with mismatch-repair deficiency.
N Engl J Med 372:2509-2520, 2015

Appointment request

DROZDOGAN AI

Explore this article together

Ask about the article and read answers alongside published sources from our site.

DROZDOGAN AI

Drozdogan Assistant

Cancers with More Genetic Abnormalities May Respond Better to Immunotherapy

Ask about the article and read answers alongside published sources from our site.

Conversation and privacy information

Drozdogan Assistant answers this conversation. Authorized site administrators may review it for quality. Do not share personal information.

Replies use OpenAI infrastructure. Questions and replies are processed by that service; conversation records are stored on our site. Do not share identifying, contact or personal health information.

0 / 1000

For information only; no personal diagnosis or treatment advice.

Related articles

Explore other articles on this topic.

Stay informed

Receive new articles and scientific updates by email.

Google Analytics runs on public pages independently of this window and may use analytics cookies. Your choice here controls external services only.

Cookie policy